Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 for metastatic castration‑resistant prostate cancer. Halda presented early phase 1/2 data showing substantial PSA declines and manageable toxicity, prompting J&J to accelerate the ongoing study and expand dose‑selection work. J&J cited the preliminary efficacy and safety profile as the rationale for the purchase and plans to scale the registrational pathway. The deal represents a major corporate bet on bifunctional small molecules that force tumor‑selective cell death, and it gives J&J control of a program that could sit alongside its androgen‑receptor franchise.